Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer : Cost consequences during outpatient surveillance in Sweden
(2016) In Future Oncology 12(8). p.1025-1038- Abstract
Aim: This study explored the cost consequences of introducing hexaminolevulinate hydrochloride-guided blue-light flexible cystoscopy (HAL BLFC) as an adjunct to white-light flexible cystoscopy compared with white-light flexible cystoscopy alone, for the detection and management of nonmuscle invasive bladder cancer in Sweden. Methods: The model evaluated 231 patients in the outpatient setting after successful initial transurethral resection of the bladder tumor. Results: HAL BLFC introduction across all risk groups resulted in minimal budget impact (+1.6% total cost/5 years, or 189 Swedish Krona [SEK] per patient/year), and translated to cost savings in intermediate- and high-risk groups from year 2. Conclusion: HAL BLFC allowed more... (More)
Aim: This study explored the cost consequences of introducing hexaminolevulinate hydrochloride-guided blue-light flexible cystoscopy (HAL BLFC) as an adjunct to white-light flexible cystoscopy compared with white-light flexible cystoscopy alone, for the detection and management of nonmuscle invasive bladder cancer in Sweden. Methods: The model evaluated 231 patients in the outpatient setting after successful initial transurethral resection of the bladder tumor. Results: HAL BLFC introduction across all risk groups resulted in minimal budget impact (+1.6% total cost/5 years, or 189 Swedish Krona [SEK] per patient/year), and translated to cost savings in intermediate- and high-risk groups from year 2. Conclusion: HAL BLFC allowed more outpatient treatment with improved recurrence detection and reduced transurethral resection of the bladder tumors, cystectomies, bed days and operating room time, with minimal cost impact across all risk groups, demonstrating the economic benefits of introducing HAL.
(Less)
- author
- Dansk, Viktor ; Malmström, Per Uno ; Bläckberg, Mats LU and Malmenäs, Maria
- publishing date
- 2016-04-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- bladder cancer, budget impact, cost-consequences model, detection, economic evaluation, fluorescence cystoscopy, fulguration, hexaminolevulinate, recurrence, Sweden
- in
- Future Oncology
- volume
- 12
- issue
- 8
- pages
- 14 pages
- publisher
- Future Medicine Ltd.
- external identifiers
-
- scopus:84961932992
- pmid:26975197
- ISSN
- 1479-6694
- DOI
- 10.2217/fon-2015-0021
- language
- English
- LU publication?
- no
- id
- 5d0da68d-4729-4abe-8a0c-098d4abb807d
- date added to LUP
- 2020-04-14 15:42:16
- date last changed
- 2024-01-17 00:55:15
@article{5d0da68d-4729-4abe-8a0c-098d4abb807d,
abstract = {{<p>Aim: This study explored the cost consequences of introducing hexaminolevulinate hydrochloride-guided blue-light flexible cystoscopy (HAL BLFC) as an adjunct to white-light flexible cystoscopy compared with white-light flexible cystoscopy alone, for the detection and management of nonmuscle invasive bladder cancer in Sweden. Methods: The model evaluated 231 patients in the outpatient setting after successful initial transurethral resection of the bladder tumor. Results: HAL BLFC introduction across all risk groups resulted in minimal budget impact (+1.6% total cost/5 years, or 189 Swedish Krona [SEK] per patient/year), and translated to cost savings in intermediate- and high-risk groups from year 2. Conclusion: HAL BLFC allowed more outpatient treatment with improved recurrence detection and reduced transurethral resection of the bladder tumors, cystectomies, bed days and operating room time, with minimal cost impact across all risk groups, demonstrating the economic benefits of introducing HAL.</p>}},
author = {{Dansk, Viktor and Malmström, Per Uno and Bläckberg, Mats and Malmenäs, Maria}},
issn = {{1479-6694}},
keywords = {{bladder cancer; budget impact; cost-consequences model; detection; economic evaluation; fluorescence cystoscopy; fulguration; hexaminolevulinate; recurrence; Sweden}},
language = {{eng}},
month = {{04}},
number = {{8}},
pages = {{1025--1038}},
publisher = {{Future Medicine Ltd.}},
series = {{Future Oncology}},
title = {{Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer : Cost consequences during outpatient surveillance in Sweden}},
url = {{http://dx.doi.org/10.2217/fon-2015-0021}},
doi = {{10.2217/fon-2015-0021}},
volume = {{12}},
year = {{2016}},
}